An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

John Dowd April is National Volunteer Month, and the Bitterroot is not short of volunteers that go above and beyond for the community. However, given that last month was […] ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers.

Researchers hope MindGlide will unlock valuable information from millions of untapped brain images that were previously difficult or impossible to understand.

Researchers had known that there was something odd about the development of MS, and attributed it to the so-called hygiene ...

Neuro-immunologist Stephen Hauser, MD, whose maverick thinking transformed the treatment landscape for patients with multiple sclerosis (MS), has received the 2025 Breakthrough Prize in Life Sciences.

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis have won ...